Nexalin Clears Nasdaq Bid-Price Test, Equity Deadline Remains
Nasdaq confirmed the company met its minimum bid-price rule, but Nexalin still faces a $2.5 million equity test by January 4.
Makkler Newsroom · Oct 8, 04:04 PM · 1 min read
Market closed· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.